2025 Annual Report
Scroll to read
Resilience (noun):
The ability to withstand disruption, adapt to evolving conditions, and emerge stronger.
The year 2025 tested the resilience of our Cure Alzheimer’s Fund community. Unprecedented disruptions in U.S. government funding and priorities challenged the biomedical research ecosystem that has yielded vital knowledge and progress in Alzheimer’s and across human health. Yet our researchers and donors persevered, focused despite all distractions on our shared goal to end Alzheimer’s disease. Together, we ensured that momentum was not lost and that progress toward our mission continued without pause.
Dear Friends,
This year was unlike any we have seen before. When we first founded Cure Alzheimer’s Fund, we knew there was a need to fund the high-risk, high-reward research that would seed the Alzheimer’s research landscape with new ideas to help patients. With our funding, scientists have been able to pursue groundbreaking new hypotheses. With preliminary data developed thanks to CureAlz support, many went on to receive government funding—more than $649* million in National Institutes of Health (NIH) funding resulted from our 2018–2022 grants—a necessary step to further move science from theory to therapy.
Never did we think this process would be upended the way it was in 2025. The federal government made repeated and unheralded sweeping changes to policies and funding that drastically impacted scientific research. Policies were announced and enforced with little notice; many were then revised or rescinded, all yielding significant instability in the scientific environment. The research community has been left reeling.
Partnering with the best scientific minds in Alzheimer’s disease research has taught Cure Alzheimer’s Fund that progress against this disease requires perseverance and adaptation in the face of obstacles, the very definition of resilience.
Although the challenges of 2025 were unprecedented, we met them the same way we face every test: with laser focus on our mission. Our donors responded to our calls to action with record-breaking support, and we, in turn, immediately put that support to work, meeting the emergent needs of our researchers by growing our research program to $38.3 million, by far the largest amount in our history. As always, we shaped our support to optimize its impact, adding emergency funding and support for brain banks and supporting laboratory staffing to stabilize the research pipeline. I am immensely proud of and grateful for the resilience demonstrated by the CureAlz donor and researcher community in 2025. Despite all obstacles, we continue to propel science forward and get closer to a cure.
As we finalized this annual report, I learned that my co-founder, Jacqui Morby, had passed away. Jacqui was an extraordinary woman who dedicated her life to pushing boundaries and improving the world around her. I am deeply saddened by this tremendous loss and can think of no greater tribute than continuing the work to find the cure for Alzheimer’s disease she fought so passionately to achieve.
On behalf of myself, the Board of Directors, and Trustees, I sincerely thank everyone who contributed to this remarkable success.
Sincerely,
Henry F. McCance
Chair, Board of Directors
* For the combined years of 2018 through 2022, the total of $87 million in grants provided to researchers from Cure Alzheimer’s Fund resulted in an extraordinary $649 million in follow-on NIH/NIA funding from 2018 through 2024.
BY THE NUMBERS
Since our inception in 2004, we have focused on funding research with the most promising likelihood of breakthroughs. We're enabling the world's leading scientists to explore bold ideas and make game-changing discoveries.
You make this possible.
A Message From Our Chief Executive Officer, Meg Smith
Our mission—pursuing a cure for a disease of the brain that strikes at the very core of who we are—is not for the faint-hearted.
Our progress has not been linear, and we know the path to success will be filled with further unexpected challenges and frustrating twists. Our mission is one of years, patience, determination, skill, and funding. But more than anything, it is a goal that will require a community to achieve, and I am truly grateful for ours.
2025 By The Numbers
Total Funds Raised
$47.2MM
Largest Gift Ever
$50MM
commitment over 5 years
Number of Donors
11,873
Research Program Spending
$38.3MM
Number of Researchers Who Received Funding
187
Grants Distributed
167
Transformational Gift Protects Vital Resources and Catalyzes Groundbreaking Discoveries
In 2025, Cure Alzheimer’s Fund received the largest single commitment in our 20-year history of funding Alzheimer’s disease research. This $50 million gift over five years will drive progress at a time when the United States government is downsizing and disrupting science in unprecedented ways. In 2025 alone, more than 7,500 grants were frozen or terminated, roughly 25,000 scientists and personnel left federal science agencies, and cuts and uncertainty forced academic institutions into hiring freezes, staff reductions, and scaled-back graduate training programs.
At this critical moment, The Cardinal Family Fund stepped up to preserve the work of early- and mid-career research scientists, critical investigations into precision medicine, and the research infrastructure and workforce needed for continued progress in Alzheimer’s research. The Fund addresses these challenges through three strategic initiatives.
The Cardinal Family Scholars Fund for Alzheimer’s Disease Research
The Cardinal Family Scholars Fund for Alzheimer’s Disease Research was established to provide stability for exceptional investigators during this critical period. The inaugural 2025 cohort of six investigators will pursue important research during this period of funding instability while developing the skills and recognition needed to become the field’s next leaders.
The Cardinal Family Scholars Fund 2025 inaugural class, from left: Hagen Tilgner, Ph.D.; Lulu Jiang, M.D., Ph.D.; Jorge Palop, Ph.D.; Andrew Yang, Ph.D.; Rachel Bennett, Ph.D.; and Doo Yeon Kim, Ph.D.
The Cardinal Family Scholars Fund 2025 inaugural class, from left: Hagen Tilgner, Ph.D.; Lulu Jiang, M.D., Ph.D.; Jorge Palop, Ph.D.; Andrew Yang, Ph.D.; Rachel Bennett, Ph.D.; and Doo Yeon Kim, Ph.D.
The Cardinal Family Emergency Relief Fund
With this gift, Cure Alzheimer’s Fund established The Cardinal Family Emergency Relief Fund to preserve momentum, protect skilled research teams, and ensure that promising Alzheimer’s research continues despite federal funding shortfalls. In early 2025, projects approved and already underway suddenly faced funding interruptions and even cancellations, despite passing rigorous peer review and securing multiyear commitments. The disruption affected research at every stage: established teams with active experiments, graduate students and postdoctoral fellows pursuing their first independent studies, and even new projects that surpassed previously announced scoring standards for federal funding. This risked slowing scientific progress, dismantling research infrastructure, and driving talented investigators and trainees out of the field.
The Cardinal Family Precision Medicine Research Fund
With the guidance of our external scientific leadership, Cure Alzheimer’s Fund has always funded research seeking safe and effective prevention and therapeutics for every member of the Alzheimer’s community. The Cardinal Family Precision Medicine Research Fund will advance research into how genetics, sex, ancestry, and environmental exposures interact to shape Alzheimer’s risk and progression across populations, producing prevention strategies, diagnostics, and treatments that work for everyone.
A Special Partnership for a Special Purpose
In 2025, CureAlz Board member and Rick Sharp Alzheimer’s Foundation (RSAF) Chair Richard Birnbaum brought together three organizations united by a shared commitment to ending the burden of disease through vital scientific discovery and progress. Through this partnership, Cure Alzheimer’s Fund, the Red Gates Foundation, and RSAF will support two key research initiatives over the next three years: the Brain Entry & Exit Consortium and the Sleep & Circadian Rhythms Consortium.
The Red Gates Foundation, established in 2020, is dedicated to empowering biomedical research to end the burden of human disease, while RSAF, founded in 2015, is dedicated to finding a cure for Alzheimer’s. Together, these partners will contribute $6 million toward more than $10 million in total funding that Cure Alzheimer’s Fund will deploy to support these cross-institutional, interdisciplinary consortia.
The Brain Entry & Exit Consortium investigates how age-related changes at the brain’s borders influence disease risk and progression, while a new Sleep & Circadian Rhythms Consortium will assess how biological clock disruptions interact with Alzheimer’s pathology.
This partnership strengthens our ability to move science forward—accelerating progress in critical areas of research and bringing us closer to meaningful advances in Alzheimer’s prevention
and treatment.
A New Way to Model Alzheimer's Earns 2025 Jeffrey L. Morby Prize
The second annual Jeffrey L. Morby Prize was awarded to senior author Andrew S. Yoo, Ph.D., and first author Zhao Sun, Ph.D., both of Washington University School of Medicine in St. Louis, for their paper, “Modeling late-onset Alzheimer’s disease neuropathology via direct neuronal reprogramming."
Their work introduces a new way to study neurons derived from patients while preserving key molecular and functional changes that develop over a lifetime. Past methods reset cells to an earlier “blank slate” state, erasing age-related characteristics and limiting their ability to model Alzheimer’s disease. In contrast, this method reprograms patient skin cells directly into neurons, allowing researchers to retain important features of aging. These lab-grown neurons reflect the patient’s own Alzheimer’s-related pathology, including—for the first time in this type of model—amyloid beta plaques, tau tangles, and neurodegeneration. This advance offers a powerful new tool for studying the disease and testing potential therapies.
From left: Henry McCance, Dr. Zhao Sun, and Jacqui Morby
From left: Henry McCance, Dr. Zhao Sun, and Jacqui Morby
“The generous support from the Jeffrey L. Morby Prize will further allow us to develop reprogramming approaches to generate different neuronal subtypes and investigate neuron-intrinsic aging mechanisms in the context of specific cell types.”
Dr. Andrew S. Yoo
Dr. Andrew S. Yoo
2025 Funded Research
Prioritizing Returns Measured in Scientific Progress—Not Potential Profits
Cure Alzheimer’s Fund measures success in scientific progress—not financial returns. In 2025, the majority of funding—92% of awards—supported early-stage research, prioritizing the identification of promising targets over proprietary drug development. The ideas we fund help advance the broader field, catalyzing new therapeutics and, when warranted, new companies. As discoveries progress, we continue to support the most promising work as it moves toward clinical application and, ultimately, patients.
Diversifying Our Research Portfolio by Following the Science
Each year, Cure Alzheimer’s Fund strategically balances our research portfolio, extending vital stability to projects demonstrating compelling progress and creating opportunity for the most promising emerging ideas.
Research Stages
In 2025, Cure Alzheimer’s Fund achieved a record high in research investment, deploying $38.3 million—a 27% increase above 2024. Our program supported 167 grants and 187 investigators advancing work across the full spectrum of Alzheimer’s research.
Foundational Research
Foundational research drives the earliest discoveries about Alzheimer’s—where important questions remain unanswered and new insights can reshape the field. This work lays the foundation for future breakthroughs and the promise of more precise approaches to Alzheimer’s prevention and treatment.
In 2025, funding supported research that reflects the diversity of people affected by Alzheimer’s, including historically understudied groups. Projects included funding brain banks to ensure donated tissue reaches labs worldwide despite cuts in federal support, advancing the Alzheimer’s Genome Project™ to better understand genetic risk and age of onset, and developing blood-based biomarkers to detect the disease earlier—before symptoms appear. We also launched the Brain Aging Consortium.
Translational Research
Translational research builds on foundational discoveries to move promising ideas closer to real-world impact. This work connects laboratory findings to approaches that ultimately may benefit patients.
In 2025, Cure Alzheimer’s Fund supported research that explored how key proteins—such as amyloid beta, tau, and APOE—influence disease progression; how immune cells in the brain, like microglia and astrocytes, may either contribute to or protect against damage; how studying Down syndrome offers insights into amyloid beta Alzheimer’s pathology; and more. This funding supported the Neuroimmune Consortium, the Fleming APOE Consortium, and the Brain Entry & Exit Consortium.
Drug Discovery and Enabling Technologies
Drug discovery research focuses on developing new approaches to prevent or treat Alzheimer’s disease. In 2025, funding addressed one of the field’s most persistent challenges: delivering treatments effectively to the brain. Researchers worked to engineer new gene therapy delivery systems that can cross the blood-brain barrier, a critical step in making advanced therapies viable.
We also supported the screening of potential drug candidates, including compounds designed to reduce toxic buildup and improve the brain’s natural clearance processes. While these efforts are still in early development, they represent important steps toward treatments that do not yet exist.
Preclinical and Clinical Drug Development and Trials
At the preclinical and clinical stages, promising therapies are refined and tested to prepare them for use in human trials and ensure that the most effective and safest approaches can move forward.
In 2025, we supported scientists exploring new ways to target neuroinflammation, including therapies engineered to reach the brain without invasive procedures. Other efforts aim to protect synapses—the connections between neurons that are essential for memory and cognition—by using precision tools to reduce harmful tau activity. We are also supporting the development of inhibitors that can modify the epigenetic code and help restore the expression of healthy genes in affected brain cells.
CureAlz deployed 2% of its research program for research operations, research materials, and scientific meetings.
Finding the Resilience Within for a Better Future
We often define resilience as an aspect of our character, something we draw on when life is hard. But science continues to reveal new wonders of the brain, including that it can have its own form of resilience. For Alzheimer’s disease, recognizing this resilience addresses one of the disease’s longtime mysteries.
Not everyone who develops amyloid plaques and tau tangles goes on to develop cognitive decline and dementia. Doctors and scientists first discovered how brain function and brain pathology may not align when examining donated brains after patients died. As technology advanced and brain scans made it possible to detect plaques and tangles in living patients, researchers found that some older adults had brains laden with enough Alzheimer’s pathology for a biological diagnosis, yet they were cognitively unimpaired. By understanding what makes these brains resilient to pathology, scientists realized they might be able to harness that power to help others.
Scientists are learning that not only do some brains naturally withstand damage, but all brains may be trained to become more resilient. In 2025, CureAlz funded research on both fronts and took unprecedented action to protect something equally important: the researchers doing the work.
Preserving Synapses to Protect Cognition
Alzheimer’s disease is associated with amyloid plaques, tau tangles, and brain cell death, but science is revealing that synapse loss is equally important. In fact, synapse loss goes hand in hand with symptoms of the disease and is one of the best predictors of dementia severity.
Synapses are the communication points between neurons. Every thought, memory, perception, and behavior is the product of synaptic activity across billions of neurons. Synapse health is a measure of brain health.
During disease progression, synapse loss follows a specific path through the brain, and not all synapses are affected. For Alzheimer’s, synapses in brain regions important for memory are affected, while synapses in areas like those controlling movement are preserved until very late in the disease, even though plaques and tangles are present.
This selective preservation—where some synapses are lost while others survive—is known as local resilience. Even more striking, some individuals display global resilience; their brains are full of plaques and tangles, yet they have no synapse loss or dementia. Together, these phenomena reveal that the brain has a remarkable capacity to resist the damage within it.
This raises a fascinating question: What is the difference between a vulnerable synapse and a resilient one, and can we shift the balance?
In 2025, Cure Alzheimer’s Fund funded research studying why synapses are lost and how to protect them.
By studying what makes synapses resilient, scientists can learn how to protect vulnerable ones, so that even if plaques and tangles develop, scientists might still be able to protect what matters most—the connections that preserve memories and thoughts.
Microglial engulfment of synapses in a human Alzheimer’s disease brain. A microglia, the brain’s immune cell, in green, is shown digesting red and blue synapses, the communication points between brain cells. Image Credit: Sunny Kumar, Ph.D., and Charles Zachary Klein, B.S., from the lab of Teresa Gomez-Isla, M.D., at Mass General Brigham.
Microglial engulfment of synapses in a human Alzheimer’s disease brain. A microglia, the brain’s immune cell, in green, is shown digesting red and blue synapses, the communication points between brain cells. Image Credit: Sunny Kumar, Ph.D., and Charles Zachary Klein, B.S., from the lab of Teresa Gomez-Isla, M.D., at Mass General Brigham.
Microglia in a mouse brain. Researchers successfully delivered a genetic marker (green) into microglia (purple), the brain’s immune cells. This is the first step in using this same method to dial down the inflammation that drives Alzheimer’s. Image credit: Paula Espinoza, B.S., from the lab of Casey A. Maguire, Ph.D., at Massachusetts General Hospital.
Microglia in a mouse brain. Researchers successfully delivered a genetic marker (green) into microglia (purple), the brain’s immune cells. This is the first step in using this same method to dial down the inflammation that drives Alzheimer’s. Image credit: Paula Espinoza, B.S., from the lab of Casey A. Maguire, Ph.D., at Massachusetts General Hospital.
The Immune System and the Brain: A Lifelong Relationship
Our immune system has two parts. One is housed within the brain and dedicated to defending it. The other, known as the peripheral immune system, circulates through the blood to protect the rest of the body. For decades, scientists thought the two systems never interacted under healthy conditions because of the protective borders separating the brain from the rest of the body. But now we understand that rather than being impenetrable walls, these borders are sophisticated checkpoints that pass messages back and forth between the brain and the body’s immune system. This allows the brain to monitor the body’s immune status and the immune system to support and fine-tune brain function.
This checkpoint system may also help explain recent findings that certain vaccines, such as the shingles vaccine, can reduce the risk of Alzheimer’s. This suggests that training the peripheral immune system—even against unrelated diseases—may somehow protect the brain. Scientists are only beginning to understand why, but it demonstrates that the two immune systems interact in ways that matter deeply for brain health and resilience to disease.
In 2025, Cure Alzheimer’s Fund funded research into how the two immune systems communicate and what happens when this communication breaks down in ways that contribute to Alzheimer’s disease.
Cure Alzheimer’s Fund also funded research exploring whether and how vaccines build resilience against Alzheimer’s. The work focused on a tuberculosis vaccine (BCG), which is known to have immune effects that extend beyond protection against tuberculosis. This research examined how the vaccine trains not only peripheral immune cells but also brain cells. The results were promising enough that this work has now advanced to a clinical trial to determine whether BCG can be used as protection against Alzheimer’s.
Supporting Scientific Resilience
Scientific advancement relies on a continuous pipeline of scientists at every stage of development—from graduate students and postdoctoral fellows to early- and mid-career researchers—to carry the work forward. A break anywhere in this pipeline can set the field back for decades.
In 2025, federal funding cuts for scientific and medical research threatened the integrity of this pipeline at multiple points.
Graduate and postdoctoral students form the backbone of active laboratories, receiving federal funding for their studies in return for lab work and classroom teaching. In 2025, these grant awards dropped to their lowest point in almost 10 years. Some students had their funding canceled with only months left to go in their programs. Without funding, they had to choose between leaving science or working without pay toward their credential.
Early- and mid-career scientists were disproportionately impacted by federal funding disruption. They depend on federal grants to build a lab, hire trainees, and pursue research. When federal funding disappeared, they faced an impossible choice: abandon their scientific work or struggle without the resources their labs need to function.
Cure Alzheimer’s Fund recognized not only the immediate harm to active science projects, but also the long-term damage of losing an entire generation of Alzheimer’s researchers. With donor support, Cure Alzheimer’s Fund provided, for the first time in our history, short-term support to 21 researchers across career stages. By keeping scientific talent engaged in Alzheimer’s research at a moment when many would have been forced out, Cure Alzheimer’s Fund supported scientific resilience, protected the scientific pipeline, and ensured funded projects stayed on track.
Meaningful discoveries emerge through sustained effort, precision, and perseverance. Scientists analyze blood-based biomarkers linked to Alzheimer’s disease. Each step contributes to improving how these markers are understood and eventually applied in clinical settings. Image credit: Isabella DiBerardino (front) and Zoe Horlick (back) from the lab of Cheryl Wellington, Ph.D., Djavad Mowafaghian Centre for Brain Health, University of British Columbia.
Meaningful discoveries emerge through sustained effort, precision, and perseverance. Scientists analyze blood-based biomarkers linked to Alzheimer’s disease. Each step contributes to improving how these markers are understood and eventually applied in clinical settings. Image credit: Isabella DiBerardino (front) and Zoe Horlick (back) from the lab of Cheryl Wellington, Ph.D., Djavad Mowafaghian Centre for Brain Health, University of British Columbia.
Looking Forward
Resilience defined our community—donors and scientists alike—in our response to 2025, and as we look ahead to 2026 and beyond, we know it will remain essential to sustaining our work and advancing science. It is also proving to be a compelling lens through which to understand Alzheimer’s disease.
New discoveries are teaching us that we can build resistance and resilience to Alzheimer’s. By identifying the lifestyle factors and environmental exposures that protect the brain, or leave it vulnerable, we have the opportunity to translate science into real, actionable protection for people long before disease takes hold.
We will always fund research pursuing the pathways and targets needed to stop or slow Alzheimer’s in those who need it, but we are equally committed to ensuring fewer people ever reach that point.
Building brain resilience requires understanding the factors that protect the brain, which is why, in 2026, we are launching the Sleep & Circadian Rhythms Consortium.
Formation of the Sleep & Circadian Rhythms Consortium
Sleep is something we all do, and science is revealing just how much it matters for brain health and Alzheimer’s risk. The circadian rhythms that regulate our bodies’ daily cycles are proving equally important. In fact, it is the circadian system that drives sleep itself, moving us through the cycles we need each night. When either is disrupted, the consequences for the brain can be significant.
Circadian rhythms coordinate timing across the entire body, and when they get out of sync, it can throw the body out of balance and create conditions that favor Alzheimer’s pathology. Sleep shapes brain health and is essential for encoding memories and for clearing waste products produced during waking hours, such as toxic amyloid beta and tau. Science has shown that disruptions in sleep and circadian rhythms are linked to increased dementia risk and that they seem to be both contributors to and consequences of emerging Alzheimer’s pathology.
Scientists think sleep and circadian rhythms can be supported with lifestyle changes and other interventions, which may offer new ways to reduce Alzheimer’s risk. But despite the growing evidence linking sleep, circadian rhythms, and Alzheimer’s disease, we don’t fully understand how they interact. That’s why, in 2026, Cure Alzheimer’s Fund is investing in this promising area by convening the Sleep & Circadian Rhythms Consortium. Composed of researchers from multiple disciplines, the consortium will work to understand how sleep and circadian rhythms influence Alzheimer’s and how that knowledge can be turned into real interventions.
Scientific Leadership
Our scientific leaders work collaboratively to determine the highest scientific priorities for our research funding and to identify the research proposals with the highest potential to accelerate progress. Two advisory groups made up of esteemed researchers share their expertise, participate in several meetings throughout the year, and work closely with our staff to facilitate collaboration and disseminate research findings to the broader community.
RESEARCH LEADERSHIP GROUP (RLG)
The RLG includes 41 leading scientists in Alzheimer’s and related fields. These leaders are the primary decision-makers regarding our overall direction, as well as specific proposals and projects. The RLG recruits investigators, conducts peer reviews on research proposals and reports, participates in quarterly meetings, and drives collaboration.
SCIENTIFIC ADVISORY BOARD (SAB)
The SAB provides guidance to Cure Alzheimer’s Fund regarding its overall scientific direction and funding efficacy. The members—who have broad experience bringing therapeutics to patients—review the entire research portfolio to ensure that CureAlz is supporting investigations into the most important issues in Alzheimer’s disease, and that our funding mechanisms accelerate the path to patients.
Source and Use of Funds
In 2025, our Total Fundraising (TFR) was $47,218,481. Cure Alzheimer’s Fund received $8,558,855 in Foundation Fundraising (FFR) from our Founders, Board of Directors, Trustees, and a core group of other donors to support our operations. Our donors contributed $38,659,626 in General Fundraising (GFR) to support our research programs.
Source of Funds
Use of Funds
Trustees
Kathleen Arnold
Jono Bacon
Carol Baxter
James Beers
Ellen Berk
Michael Berk
Anoosheh Bostani
Jeff and Blakeley Buratto
Thomas Clarke
Shari Crotty
Karen Friend, Ph.D., ACPS
Christina Kohnen
Jeanne Leszczynski
Edie and John Randall
Nancy and Bryan Ruez
Lindsey Simon
Working Together for a Cure
The Power of Community
Alzheimer’s disease inflicts a terrible toll, but it also reveals the strength and resilience of a community determined to find a cure. Each person’s experience is unique, yet together our resilience fuels progress—raising funds, awareness, and hope. By supporting research in ways that reflect their passions and abilities, our donors are helping to move us closer to a future without Alzheimer’s.
With Your Partnership, We Will Find a Cure
There are many ways to be part of the solution to find a cure. With your support, we can truly make a difference in our understanding of Alzheimer’s and bring hope to the millions of individuals and their families who are affected by this disease.
Our Board of Directors, Trustees, and a core group of other donors direct their donations to our overhead expenses so that 100% of general donations support our research program.
Make an Impact
● Make a one-time or recurring gift online by credit card, PayPal, or Venmo. Visit give.curealz.org/annualreport.
● Mail a check payable to Cure Alzheimer’s Fund and send to 34 Washington St., Suite 230, Wellesley Hills, MA 02481
● Recommend a gift to Cure Alzheimer’s Fund through your donor-advised fund (DAF).
● Donate by telephone by calling 781-237-3800. Our business hours are 9 a.m.–5 p.m. ET.
● Support CureAlz with stocks, mutual fund shares, or other appreciated assets while potentially reducing your tax burden. Gifts may be sent electronically via wire transfer. Please contact Laurel Lyle at LLyle@curealz.org.
● Make a tax-free gift to CureAlz through a qualified charitable distribution (QCD): if you are age 70½ or older, you can donate up to $111,000 directly from your individual retirement account (IRA) in 2026. Please contact Ally DeCruz at adecruz@curealz.org.
● Become a community fundraiser. Visit give.curealz.org/hero or email hero@curealz.org to connect with a member of our team.
You can create a lasting legacy… by including Cure Alzheimer’s Fund in your will or trust, through a charitable gift annuity, or by naming CureAlz as a beneficiary of a retirement or financial account, insurance policy, or donor-advised fund. To explore planned giving options that best meet your needs, contact us at legacy@curealz.org.
Download a copy of the 2025 Annual Report
Built with Shorthand